Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

REFERENCES

• Al-Ali, H. K., M. C. Heinrich, T. Lange, R. Krahl, M. Mueller, C. Muller, D. Niederwieser, B. J. Druker, and M. W. Deininger. 2004. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol. J. 5:55–60.
   PubMedGoogle Scholar
• Aman, M. J., T. D. Lamkin, H. Okada, T. Kurosaki, and K. S. Ravichandran. 1998. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273:33922–33928.
   PubMed Web of Science ®Google Scholar
• Branford, S., Z. Rudzki, S. Walsh, A. Grigg, C. Arthur, K. Taylor, R. Herrmann, K. P. Lynch, and T. P. Hughes. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472–3475.
   PubMed Web of Science ®Google Scholar
• Corbin, A. S., E. Buchdunger, F. Pascal, and B. J. Druker. 2002. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. 277:32214–32219.
   PubMed Web of Science ®Google Scholar
• Corbin, A. S., P. La Rosee, E. P. Stoffregen, B. J. Druker, and M. W. Deininger. 2003. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611–4614.
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob, S. W., V. Guez, G. Fendrich, J. D. Griffin, D. Fabbro, P. Furet, J. Liebetanz, J. Mestan, and P. W. Manley. 2004. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 4:285–299.
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., R. A. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830.
   PubMed Web of Science ®Google Scholar
• Deininger, M. W., J. M. Goldman, and J. V. Melo. 2000. The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356.
   PubMed Web of Science ®Google Scholar
• Druker, B. J., C. L. Sawyers, H. Kantarjian, D. J. Resta, S. F. Reese, J. M. Ford, R. Capdeville, and M. Talpaz. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Druker, B. J., M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, and C. L. Sawyers. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Gishizky, M. L., and O. N. Witte. 1992. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256:836–839.
   PubMed Web of Science ®Google Scholar
• Goldman, J. M., and J. V. Melo. 2003. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N. Engl. J. Med. 349:1451–1464.
   PubMed Web of Science ®Google Scholar
• Gorre, M. E., M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. N. Rao, and C. L. Sawyers. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880.
   PubMed Web of Science ®Google Scholar
• Helgason, C. D., J. E. Damen, P. Rosten, R. Grewal, P. Sorensen, S. M. Chappel, A. Borowski, F. Jirik, G. Krystal, and R. K. Humphries. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1610–1620.
   PubMed Web of Science ®Google Scholar
• Hochhaus, A., S. Kreil, A. S. Corbin, P. La Rosee, M. C. Muller, T. Lahaye, B. Hanfstein, C. Schoch, N. C. Cross, U. Berger, H. Gschaidmeier, B. J. Druker, and R. Hehlmann. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196.
   PubMed Web of Science ®Google Scholar
• Kreuzer, K. A., P. Le Coutre, O. Landt, I. K. Na, M. Schwarz, K. Schultheis, A. Hochhaus, and B. Dorken. 2003. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann. Hematol. 82:284–289.
   PubMed Web of Science ®Google Scholar
• Lugo, T. G., A. M. Pendergast, A. J. Muller, and O. N. Witte. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079–1082.
   PubMed Web of Science ®Google Scholar
• McLaughlin, J., E. Chianese, and O. N. Witte. 1987. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84:6558–6562.
   PubMed Web of Science ®Google Scholar
• Miething, C., S. Feihl, C. Mugler, R. Grundler, N. von Bubnoff, F. Lordick, C. Peschel, and J. Duyster. 2006. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 20:650–657.
   PubMed Web of Science ®Google Scholar
• Miething, C., C. Mugler, R. Grundler, J. Hoepfl, R. Y. Bai, C. Peschel, and J. Duyster. 2003. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity toward imatinib in vivo. Leukemia 17:1695–1699.
   PubMedGoogle Scholar
• Million, R. P., N. Harakawa, S. Roumiantsev, L. Varticovski, and R. A. Van Etten. 2004. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol. Cell. Biol. 24:4685–4695.
   PubMedGoogle Scholar
• Nagar, B., W. G. Bornmann, P. Pellicena, T. Schindler, D. R. Veach, W. T. Miller, B. Clarkson, and J. Kuriyan. 2002. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:4236–4243.
   PubMed Web of Science ®Google Scholar
• Nagar, B., O. Hantschel, M. A. Young, K. Scheffzek, D. Veach, W. Bornmann, B. Clarkson, G. Superti-Furga, and J. Kuriyan. 2003. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112:859–871.
   PubMed Web of Science ®Google Scholar
• Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780–3792.
   PubMed Web of Science ®Google Scholar
• Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392–8396.
   PubMed Web of Science ®Google Scholar
• Pluk, H., K. Dorey, and G. Superti-Furga. 2002. Autoinhibition of c-Abl. Cell 108:247–259.
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne, C., J. L. Lai, S. Darre, T. Facon, and C. Preudhomme. 2003. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N. Engl. J. Med. 348:2265–2266.
   PubMedGoogle Scholar
• Roche-Lestienne, C., V. Soenen-Cornu, N. Grardel-Duflos, J. L. Lai, N. Philippe, T. Facon, P. Fenaux, and C. Preudhomme. 2002. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can preexist to the onset of treatment. Blood 100:1014–1018.
   PubMed Web of Science ®Google Scholar
• Roumiantsev, S., I. E. de Aos, L. Varticovski, R. L. Ilaria, and R. A. Van Etten. 2001. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97:4–13.
   PubMed Web of Science ®Google Scholar
• Roumiantsev, S., N. P. Shah, M. E. Gorre, J. Nicoll, B. B. Brasher, C. L. Sawyers, and R. A. Van Etten. 2002. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA 99:10700–10705.
   PubMed Web of Science ®Google Scholar
• Rush, J., A. Moritz, K. A. Lee, A. Guo, V. L. Goss, E. J. Spek, H. Zhang, X. M. Zha, R. D. Polakiewicz, and M. J. Comb. 2005. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23:94–101.
   PubMed Web of Science ®Google Scholar
• Sattler, M., M. G. Mohi, Y. B. Pride, L. R. Quinnan, N. A. Malouf, K. Podar, F. Gesbert, H. Iwasaki, S. Li, R. A. Van Etten, H. Gu, J. D. Griffin, and B. G. Neel. 2002. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:479–492.
   PubMed Web of Science ®Google Scholar
• Sattler, M., S. Verma, Y. B. Pride, R. Salgia, L. R. Rohrschneider, and J. D. Griffin. 2001. SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J. Biol. Chem. 276:2451–2458.
   PubMedGoogle Scholar
• Shah, N. P., J. M. Nicoll, B. Nagar, M. E. Gorre, R. L. Paquette, J. Kuriyan, and C. L. Sawyers. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125.
   PubMed Web of Science ®Google Scholar
• Smith, K. M., R. Yacobi, and R. A. Van Etten. 2003. Autoinhibition of Bcr-Abl through its SH3 domain. Mol. Cell 12:27–37.
   PubMedGoogle Scholar
• Soverini, S., G. Martinelli, G. Rosti, S. Bassi, M. Amabile, A. Poerio, B. Giannini, E. Trabacchi, F. Castagnetti, N. Testoni, S. Luatti, A. de Vivo, D. Cilloni, B. Izzo, M. Fava, E. Abruzzese, D. Alberti, F. Pane, G. Saglio, and M. Baccarani. 2005. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol. 23:4100–4109.
   Google Scholar
• von Bubnoff, N., F. Schneller, C. Peschel, and J. Duyster. 2002. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359:487–491.
   PubMed Web of Science ®Google Scholar
• Willis, S. G., T. Lange, S. Demehri, S. Otto, L. Crossman, D. Niederwieser, E. P. Stoffregen, S. McWeeney, I. Kovacs, B. Park, B. J. Druker, and M. W. Deininger. 2005. High sensitivity detection of Bcr-Abl kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106:2128–2137.
   PubMed Web of Science ®Google Scholar
• Yamamoto, M., T. Kurosu, K. Kakihana, D. Mizuchi, and O. Miura. 2004. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem. Biophys. Res. Commun. 319:1272–1275.
   PubMedGoogle Scholar
• Zhang, X., and R. Ren. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829–3840.
   PubMed Web of Science ®Google Scholar